156 related articles for article (PubMed ID: 16517448)
1. The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy.
Gianfrancesco F; Wang RH; Nasrallah HA
Ann Clin Psychiatry; 2006; 18(1):9-17. PubMed ID: 16517448
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database.
Gianfrancesco F; White R; Wang RH; Nasrallah HA
J Clin Psychopharmacol; 2003 Aug; 23(4):328-35. PubMed ID: 12920407
[TBL] [Abstract][Full Text] [Related]
3. New-onset type-2 diabetes associated with atypical antipsychotic medications.
Lambert MT; Copeland LA; Sampson N; Duffy SA
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):919-23. PubMed ID: 16581171
[TBL] [Abstract][Full Text] [Related]
4. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Gianfrancesco FD; Grogg AL; Mahmoud RA; Wang RH; Nasrallah HA
J Clin Psychiatry; 2002 Oct; 63(10):920-30. PubMed ID: 12416602
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
[TBL] [Abstract][Full Text] [Related]
7. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.
Citrome LL; Holt RI; Zachry WM; Clewell JD; Orth PA; Karagianis JL; Hoffmann VP
Ann Pharmacother; 2007 Oct; 41(10):1593-603. PubMed ID: 17785613
[TBL] [Abstract][Full Text] [Related]
8. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients.
Aparasu RR; Jano E; Johnson ML; Chen H
Am J Geriatr Pharmacother; 2008 Oct; 6(4):198-204. PubMed ID: 19028375
[TBL] [Abstract][Full Text] [Related]
9. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design.
Gianfrancesco F; Pesa J; Wang RH; Nasrallah H
Am J Health Syst Pharm; 2006 Mar; 63(5):431-41. PubMed ID: 16484517
[TBL] [Abstract][Full Text] [Related]
10. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
11. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
Keller R; Mongini F
Neurol Sci; 2002 Dec; 23(5):233-5. PubMed ID: 12522680
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
McIntyre RS; Jerrell JM
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis.
Baker RA; Pikalov A; Tran QV; Kremenets T; Arani RB; Doraiswamy PM
Psychopharmacol Bull; 2009; 42(1):11-31. PubMed ID: 19204649
[TBL] [Abstract][Full Text] [Related]
15. [Antipsychotic treatment of dementia after publication of new risks].
Wittmann M; Hausner H; Hajak G; Haen E;
Psychiatr Prax; 2010 Mar; 37(2):68-70. PubMed ID: 19724997
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.
Gianfrancesco F; Grogg A; Mahmoud R; Wang RH; Meletiche D
Clin Ther; 2003 Apr; 25(4):1150-71. PubMed ID: 12809963
[TBL] [Abstract][Full Text] [Related]
17. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.
Ramaswamy K; Masand PS; Nasrallah HA
Ann Clin Psychiatry; 2006; 18(3):183-94. PubMed ID: 16923657
[TBL] [Abstract][Full Text] [Related]
18. New-onset diabetes mellitus associated with quetiapine.
Procyshyn RM; Pande S; Tse G
Can J Psychiatry; 2000 Sep; 45(7):668-9. PubMed ID: 11056833
[No Abstract] [Full Text] [Related]
19. Relationship of atypical antipsychotics with development of diabetes mellitus.
Citrome LL; Jaffe AB
Ann Pharmacother; 2003 Dec; 37(12):1849-57. PubMed ID: 14632602
[TBL] [Abstract][Full Text] [Related]
20. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
Silvestre JS; Prous J
Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
